AACR Annual Meeting 2024
San Diego Convention Center, San Diego, California
April 05, 2024 - April 10, 2024We are delighted that we were able to connect with so many scientists at the 2024 AACR Annual Meeting. While the event may have ended, your cutting-edge research has not! Check out our poster presentations from the event and explore our resources for cancer diagnostics and drug development below to see how we can support your oncology and immuno-oncology studies.
Did you miss us at booth #1413 and would like to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
|
We are offering 10% off Checkpoint and CAR-T Target Reporter Models* Use promo code ATCC-000028 at checkout to take advantage of this special discount. This limited-time offer is effective from April 1 - May 15, 2024, so place your order before time runs out! *Offer is effective from April 1st – May 15th, 2024. The 10% discount applies only to ATCC Checkpoint and CAR-T Target Reporter Models; all other items are excluded from this promotion. For non-profit customers, the promotional discount is applied to the customer-specific pricing. The promo code must be applied at the time of checkout. The promo code must be applied in the “Promotional code” field in the shopping cart. U.S. customers only. Void where prohibited. Restrictions may apply. Limit 20 vials. Order Checkpoint Reporter Models Order CAR-T Target Reporter Models |
Check out our poster presentations
Luciferase reporter cell lines allow simultaneous incorporation of tumor cells, innate immune cells, and adaptive immune cells for in-depth immune checkpoint studies
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: Sunday, April 7, 2024
Time: 1:30 PM – 5:00 PM
Abstract number: 75
Pancreatic cancer organoids from the Human Cancer Models Initiative biobank reflect disease genotypes, capture patient heterogeneity, and are amenable to therapeutic screening
Presenter: Stephen Friend, MS, Biologist, ATCC
Date: Tuesday, April 9, 2024
Time: 9:00 AM – 12:30 PM
Abstract number: 4239
Meet the presenters
Hyeyoun Chang, PhD
Scientist, ATCC
Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School.
Stephen Friend, MS
Biologist, ATCC
Stephen Friend is a Biologist in the Microphysiological Systems group of the R&D department at ATCC. He started his scientific career at ATCC three years ago after receiving his Master’s Degree in Biomedical Science from Hood College. Stephen has worked on a variety of projects at ATCC including primary cell and cancer cell line culture, airway modeling and optimization using air-liquid-interface techniques, and the development and production of 3D patient-derived cancer organoids from various primary tissues.
Human Cancer Models Initiative
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.
ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Find next-generation modelsDownload a PDF of our featured literature
Brochure
Immuno-oncology Capabilities
ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.
MoreDevelopment and performance evaluation of a modified xeno-free McCoy's 5A medium formulation: McCoy’s 5A Medium, ABP-Free (ATCC 30-2011)
Our newly developed animal by-product free McCoy’s 5A medium was tested across several ATCC cell lines for performance and was found to be a suitable substitute for the current McCoy’s 5A Medium.
MoreA Novel NIH/3T3 Clonal Derivative: NIH/3T3.2 Re-Developed as a Cell Model for Contact Inhibition Research
This study showcases the development of a NIH/3T3 clonal derivative that maintains the contact inhibition property associated with this cell line.
More
Brochure
Checkpoint Luciferase Reporter Cells
To facilitate large-scale drug discovery of immune checkpoint inhibitors, ATCC created tumor and immune cell lines with high endogenous expression of checkpoint inhibitory and co-stimulatory expression levels.
More
Brochure
CAR-T Target Luciferase Reporter Cells
ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.
More
Brochure
hTERT-immortalized Primary Cells
Enjoy the best of all worlds with human telomerase reverse transcriptase (hTERT)-immortalized Primary Cells from ATCC.
More
Application note
Luciferase Reporter Cancer Cell Lines Facilitate CAR-T Development
This report describes ATCC luciferase reporter solid and liquid tumor cell lines that express tumor antigens such as CD19, CD20, and HER2. Learn how you can incorporate these target cells into your T-Cell cytotoxicity assays to enable your breakthroughs in immuno-oncology.
More
Brochure
Cell Lines by Gene Mutation
This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.
More
Brochure
Genetic Alteration Cell Panel
A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.
More
Brochure
Isogenic Cell Lines
With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.
More
Brochure
Tumor/Normal Matched Cell Line Pairs
Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.
MoreHigh Performance Media, Sera, and Reagents
Using ATCC high-performance media, sera, and reagents will ensure robust, continuous cell growth, consistent performance, and minimum cell loss when reviving cells from cryopreservation.
MoreContact us today
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.
